CNRS, TIMC-IMAG UMR 5525, Joseph-Fourier University-Grenoble 1, Themas, Domaine de la Merci, 38706, La Tronche Cedex, France,
Int J Clin Pharm. 2014 Jun;36(3):513-8. doi: 10.1007/s11096-014-9916-y. Epub 2014 Mar 15.
Guidelines recommend use of the oral route whenever possible to treat or prevent hypokalemia. Although a myriad of papers have been published regarding intravenous to oral (IV to PO) therapy conversion programs and about clinical pharmacy services provided in hospitals, little is known on the role of hospital pharmacists in promoting the oral route for potassium administration.
The aim of this work was to describe the frequency of interventions related to IV to PO potassium therapy conversions performed by hospital pharmacists. Setting French hospitals recording pharmacist's interventions on the website tool of the French Society of Clinical Pharmacy.
From the pharmacist's interventions (PI) dataset recorded we extracted all interventions related to potassium IV to PO conversion. We assessed the acceptance rate of these PI by prescribers. Additional free text information in the dataset was analysed.
IV to PO potassium therapy conversions related to potassium chloride.
From January 2007 to December 2010, 87 hospitals recorded 1,868 PIs concerning IV to PO therapy conversion. Among these, 16 (<1 %) concerned potassium chloride. They were recorded by four hospitals (4.6 %) with respectively 12, 2, 1 and 1 PIs. Six PIs were accepted by physicians and the prescriptions were modified.
PIs to promote the administration of potassium by the oral route are extremely rare. Our results and scarce previously published data reveal that this field of practice remains almost unexplored. These findings highlight an important gap in the field of intravenous to oral therapy programs. This situation must be regarded as unsatisfactory and should lead to setting up more education and research programs.
指南建议尽可能通过口服途径治疗或预防低钾血症。尽管已经发表了大量关于静脉到口服(IV 到 PO)治疗转换方案以及医院提供的临床药学服务的论文,但对于医院药师在促进口服补钾方面的作用却知之甚少。
本研究旨在描述医院药师进行的 IV 到 PO 钾治疗转换相关干预的频率。该研究在法国临床药学学会网站工具上记录药师干预的法国医院中开展。
从记录的药师干预(PI)数据集中,我们提取了所有与 IV 到 PO 钾转换相关的干预措施。我们评估了这些 PI 被开方者接受的情况。对数据集内的其他自由文本信息进行了分析。
与氯化钾相关的 IV 到 PO 钾治疗转换。
2007 年 1 月至 2010 年 12 月,87 家医院记录了 1868 例与 IV 到 PO 治疗转换相关的 PI。其中 16 例(<1%)与氯化钾有关。它们由 4 家医院(4.6%)记录,分别为 12、2、1 和 1 例。6 例 PI 被医生接受,处方被修改。
促进口服补钾的 PI 极为罕见。我们的结果和以前发表的稀缺数据表明,这一实践领域几乎没有得到探索。这些发现突出了静脉到口服治疗方案领域的一个重要空白。这种情况必须被视为不令人满意的,并应导致更多的教育和研究计划的制定。